Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:atuzaginstatIndication |
gptkb:Alzheimer's_disease
|
| gptkbp:atuzaginstatTarget |
gptkb:Porphyromonas_gingivalis
|
| gptkbp:CEO |
gptkb:Casey_Lynch
|
| gptkbp:developedDrugCandidate |
atuzaginstat
|
| gptkbp:focusesOn |
gptkb:Alzheimer's_disease
neurodegenerative diseases |
| gptkbp:foundedIn |
2012
|
| gptkbp:founder |
gptkb:Stephen_Dominy
gptkb:Casey_Lynch |
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cortexyme
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableEvent |
FDA clinical hold in 2021
Phase 2/3 GAIN trial for atuzaginstat |
| gptkbp:publiclyTraded |
true
|
| gptkbp:renamed |
gptkb:Quince_Therapeutics
2022 |
| gptkbp:stockSymbol |
gptkb:CRTX
|
| gptkbp:website |
https://www.cortexyme.com/
|
| gptkbp:bfsParent |
gptkb:Samsara_BioCapital
|
| gptkbp:bfsLayer |
6
|